These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Competitive antagonism at thromboxane receptors in human platelets. Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Nicolaou KC; Magolda RL; Smith JB; Aharony D; Smith EF; Lefer AM Proc Natl Acad Sci U S A; 1979 Jun; 76(6):2566-70. PubMed ID: 288046 [TBL] [Abstract][Full Text] [Related]
4. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
5. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
6. Blockade of thromboxane and the prevention of eicosanoid-induced sudden death in mice. Darius H; Lefer AM Proc Soc Exp Biol Med; 1985 Nov; 180(2):364-8. PubMed ID: 2996012 [TBL] [Abstract][Full Text] [Related]
7. [Effects of thromboxane A2 synthetase inhibitor, DP-1904 on the action of vasoactive substances in rabbit blood vessel smooth muscle preparations]. Shimizu K; Kobayashi J; Iwanaga T; Kuratomi Y; Kitamura S Nihon Kyobu Shikkan Gakkai Zasshi; 1989 May; 27(5):591-6. PubMed ID: 2615099 [TBL] [Abstract][Full Text] [Related]
8. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Burke SE; Lefer AM; Nicolaou KC; Smith GM; Smith JB Br J Pharmacol; 1983 Feb; 78(2):287-92. PubMed ID: 6831115 [TBL] [Abstract][Full Text] [Related]
9. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. Yu SM; Wu TS; Teng CM Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768 [TBL] [Abstract][Full Text] [Related]
11. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Lefer AM; Smith EF; Araki H; Smith JB; Aharony D; Claremon DA; Magolda RL; Nicolaou KC Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1706-10. PubMed ID: 6929517 [TBL] [Abstract][Full Text] [Related]
12. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
13. Constriction of cat coronary arteries by synthetic thromboxane A2 and its antagonism. Smith JB; Yanagisawa A; Zipkin R; Lefer AM Prostaglandins; 1987 Jun; 33(6):777-82. PubMed ID: 3671730 [TBL] [Abstract][Full Text] [Related]
14. Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle. Harris DN; Greenberg R; Phillips MB; Michel IM; Goldenberg HJ; Haslanger MF; Steinbacher TE Eur J Pharmacol; 1984 Aug; 103(1-2):9-18. PubMed ID: 6090180 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle. Yanagisawa A; Smith JA; Brezinski ME; Lefer AM Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of coronary vasoconstriction induced by carbocyclic thromboxane A2. Smith EF; Lefer AM; Nicolaou KC Am J Physiol; 1981 Apr; 240(4):H493-7. PubMed ID: 6261592 [TBL] [Abstract][Full Text] [Related]
17. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor. Imura Y; Terashita Z; Shibouta Y; Nishikawa K Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770 [TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death. Lefer AM; Okamatsu S; Smith EF; Smith JB Thromb Res; 1981 Aug; 23(3):265-73. PubMed ID: 6795758 [No Abstract] [Full Text] [Related]
20. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R; Nenci GG; Gresele P J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]